Article
ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases.
International journal of hematology - 1 Jan 2014
Aoe Michinori, Shimada Akira, Muraoka Michiko, Washio Kana, Nakamura Yoshimi, Takahashi Takahide, Imada Masahide, Watanabe Toshiyuki, Okada Ken, Nishiuchi Ritsuo, Miyamura Takako, Chayama Kosuke, Shibakura Misako, Oda Megumi, Morishima Tsuneo
Abstract excerpt
The tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) revolutionized the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL), which had showed poor prognosis before the dawn of IM treatment. However, if Ph-ALL patients showed IM resistance due to ABL kinase mutation, second-generation TKI, dasatinib or nilotinib, was recommended. We treated 4 pediatric Ph-ALL patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.